Medicare

In Medicare beneficiaries hospitalized for acute MI, 30-day mortality rates did not vary by Medicare plan type by 2018, researchers reported in JAMA.

Results showed safety-net hospitals and hospitals with greater populations of Black and Hispanic patients have struggled to meet the lower spending benchmarks implemented by Medicare and the Comprehensive Care for Joint Replacement model.

Medicare Advantage beneficiaries who required surgery for stomach, pancreas or liver cancers had lower access to high-volume hospitals than those enrolled in traditional Medicare plans, according to study results.

Veterans with end-stage kidney disease receiving hospice financed by the Veterans Health Administration were more likely to receive concurrent treatments than those receiving Medicare-financed hospice, according to recently published data.

While applauding CMS’ 2023 Medicare Physician Fee Schedule for expanding Medicare coverage of colorectal cancer screening, gastrointestinal societies also voiced concerns over the reimbursement cuts to gastroenterology services.

The American Association of Orthopaedic Surgeons has issued a letter urging Congress to pass two bills that would mitigate the Medicare physician pay cuts set to go into effect on Jan. 1, 2023, according to a press release.

The 2023 Medicare Physician Fee Schedule does not reflect the important role infectious disease physicians play in safeguarding public health and is a “serious setback” to the ID workforce, the Infectious Diseases Society of America said.

Medicare beneficiaries have less geographic accessibility to substance use disorder treatment facilities, as Medicare acceptance is lower compared with other kinds of payment, per a study published in JAMA Network Open.

GRAPEVINE, Texas — A speaker recommended risk-adjusted surgeon reimbursement after data showed mean reimbursement following total joint arthroplasty was lower for high-risk Medicare patients compared with their healthy counterparts.

In the United Kingdom, Germany and Spain, dapagliflozin with standard therapy is a cost-effective treatment for chronic kidney disease, according to data published in the Clinical Journal of the American Society of Nephrology.